Literature DB >> 2208008

Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification.

T Obara1, Y Fujimoto, Y Kanaji, T Okamoto, A Hirayama, Y Ito, T Kodama.   

Abstract

The previous cytometric studies on parathyroid tumors have provided conflicting data regarding the relationship between DNA content and histopathology, resulting from differences in technical methods and data analysis. This study measured nuclear DNA of parathyroid tumors by flow cytometry in fresh material and determined whether DNA aneuploidy really assists in making a pathologic diagnosis of carcinoma or not. From May 1987 through April 1989, 65 consecutive patients operated on for primary hyperparathyroidism had DNA analysis of the freshly excised parathyroid tumors. Three of the patients had metastatic lesions of parathyroid carcinoma in the lung, cervical lymph nodes, and lung and mediastinal lymph nodes, respectively. Pathologic classifications of the lesions from the other 62 patients were 54 adenomas, four carcinomas, and four hyperplasias. In all the latter patients, hyperplasia was associated with a multiple endocrine neoplasia syndrome. Unequivocal evidence of aneuploidy was found in all of the metastatic lesions and 60% of the primary lesions of the carcinomas, in 9% of the adenomas and in 50% of the hyperplasias. Therefore, parathyroid carcinomas were more apt to be aneuploid than were adenomas (P = 0.0015, both-sided testing). In each of the cases of aneuploid hyperplasia, a small aneuploid peak was found. The high incidence of aneuploidy in patients with multiple endocrine neoplasia type 1 may indicate the presence of clonal heterogeneity of hyperplastic glands and the presence of an abnormal subset of cells that have malignant potential. Cell distribution analysis did not provide any significant information beyond ploidy level. In conclusion, DNA flow cytometric analysis of DNA ploidy patterns is a valuable adjunct to the histopathologic diagnosis of parathyroid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208008     DOI: 10.1002/1097-0142(19901001)66:7<1555::aid-cncr2820660721>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  The study of endocrine tumors by flow and image cytometry.

Authors:  Ingrid Zbieranowski; David Murray
Journal:  Endocr Pathol       Date:  1992-06       Impact factor: 3.943

2.  Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor.

Authors:  T D'Adda; A Amorosi; G Bussolati; M L Brandi; C Bordi
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 3.  Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.

Authors:  Mohamed Abdelgadir Adam; Brian R Untch; John A Olson
Journal:  Oncologist       Date:  2010-01-05

Review 4.  Parathyroid carcinoma: etiology, diagnosis, and treatment.

Authors:  Takahiro Okamoto; Masatoshi Iihara; Takao Obara; Toshihiko Tsukada
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 5.  Diagnosis and treatment of patients with parathyroid carcinoma: an update and review.

Authors:  T Obara; Y Fujimoto
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

6.  Clinical course of metastatic parathyroid cancer.

Authors:  K Sandelin; O Tullgren; L O Farnebo
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

7.  Prognostic factors in parathyroid cancer: a review of 95 cases.

Authors:  K Sandelin; G Auer; L Bondeson; L Grimelius; L O Farnebo
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

8.  Resection of a large ectopic parathyroid adenoma: A case report.

Authors:  Seijiro Sato; Akihiko Kitahara; Terumoto Koike; Takehisa Hashimoto; Riuko Ohashi; Noriko Motoi; Masanori Tsuchida
Journal:  Int J Surg Case Rep       Date:  2016-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.